Resolution Therapeutics Announces £63.5 Million Series B …

Oct 3, 2024  · The proceeds from the Series B financing will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy …


Install CouponFollow Chrome Extension   CouponFollow Extension

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024  · The proceeds from the Series B financing will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy …

prnewswire.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024  · Edinburgh and London, UK, 3 October 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company focused on unlocking the …

resolution-tx.com

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024  · Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the …

yahoo.com

£63
OFF

Resolution Therapeutics Raises £63.5 Million In Series B Financing …

6 days from now

Oct 3, 2024  · The Series B financing brings the total amount raised by Resolution to £101.4 million. Following the drawdown of the full Series B financing, Syncona's ownership stake in …

pharmiweb.com

$83
OFF

Resolution Scores $83m To Develop Macrophage Cell Therapies

6 days from now

Oct 3, 2024  · Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based company plans to use the money to …

pharmaceutical-technology.com

£63
OFF

Resolution Therapeutics | Pre-clinical Companies | Portfolio

6 days from now

Resolution Therapeutics was founded by Syncona and is developing macrophage cell therapies to repair inflammatory organ damage. ... Raised in Series B financing in October 2024 £63.5m. ...

synconaltd.com

£64
OFF

Resolution’s £64M Series B To Advance Macrophage Cell Therapy

6 days from now

Oct 3, 2024  · A preview of the next edition of BioWorld, Oct. 3, 2024. Resolution Therapeutics Ltd. is preparing for a phase I/II trial of its autologous engineered macrophage cell therapy, RTX …

bioworld.com

$85
OFF

Resolution Therapeutics' Macrophage Therapy Raises $85 Million

6 days from now

Oct 3, 2024  · A week after Vicebio’s $100 million series B round, another U.K.-based biotech makes the headlines. Today, Resolution Therapeutics, a clinical-stage biotech company, …

labiotech.eu

£63
OFF

Resolution Therapeutics Raises £63.5M In Series B Financing

6 days from now

Oct 3, 2024  · Resolution Therapeutics, an Edinburgh, Scotland, and London, UK-based clinical-stage biopharmaceutical company, raised £63.5M in Series B funding.. The round was led by …

finsmes.com

£63
OFF

Edinburgh Innovations | Spinout Resolution Therapeutics …

6 days from now

Jun 5, 2024  · Biotech spinout Resolution Therapeutics has announced it has raised £63.5 million in a series B financing round led by healthcare investor Syncona Ltd. The company, founded …

ed.ac.uk

£63
OFF

Resolution Therapeutics Announces £63.5 Million Series B …

6 days from now

Oct 3, 2024  · EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on …

epicos.com

$83
OFF

Resolution Therapeutics Raises £63.5M In Series B Funding

6 days from now

Oct 3, 2024  · NEW YORK – Resolution Therapeutics on Thursday said it has raised £63.5 million ($83.3 million) in Series B financing led by Syncona. Edinburgh, UK-based Resolution will use …

precisionmedicineonline.com

£63
OFF

Resolution Therapeutics Announces New Clinical And Preclinical …

6 days from now

Nov 11, 2024  · Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment Resolution Therapeutics Limited ("Resolution"), a clinical-stage …

prnewswire.com

$63
OFF

Resolution Therapeutics Secures $63.5 Million In Series B …

6 days from now

Resolution Therapeutics, a pioneering biotechnology company based at the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, has successfully raised an …

leadsontrees.com

£63
OFF

Resolution Therapeutics - Unlocking Regenerative Macrophage …

6 days from now

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment. Resolution raises £63.5M series B financing from Syncona and appoints Paul Sekhri as Chair …

resolution-tx.com

FAQs about Resolution Therapeutics Announces £63.5 Million Series B … Coupon?

How much did resolution raise in Series B financing?

Resolution announced this week that it had raised £63.5 million (US$ 83 million) in Series B financing. The round adds to an earlier £26.6 million (US$ 35 million) Series A financing in 2020. ...

What is resolution Therapeutics?

About Resolution Therapeutics Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. ...

Is resolution a regenerative biopharmaceutical company?

EDINBURGH, Scotland and LONDON, Oct. 3, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces it has raised £63.5 million in Series B financing. ...

Will rtx001 go into clinical trials?

Resolution plans to use the new financing to progress RTX001, its lead candidate, into clinical trials. RTX001 is an engineered autologous macrophage cell therapy for treatment of end stage liver disease. ...

What is resolution's lead candidate therapy?

Resolution’s lead candidate therapy is designed to regenerate the liver in end stage liver disease patients by increasing anti-fibrotic and anti-inflammatory effects. ...

What is the clinical development program for rtx001?

The clinical development program for RTX001 currently consists of two clinical studies. The ongoing OPAL study is a multi-center natural history study in patients with liver cirrhosis who have been hospitalized for the first time with hepatic decompensation. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension